Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVRO AVROBIO (AVRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About AVROBIO Stock (NASDAQ:AVRO) 30 days 90 days 365 days Advanced Chart Get AVROBIO alerts:Sign Up Key Stats Today's Range$1.38▼$1.4450-Day Range$1.40▼$18.2452-Week Range$0.88▼$1.65Volume206,800 shsAverage Volume269,831 shsMarket Capitalization$62.85 millionP/E Ratio2.03Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AVRO Stock News HeadlinesL'action TECX atteint un sommet sur 52 semaines à 53,41$December 25, 2024 | fr.investing.comL'action TECX atteint un sommet sur 52 semaines à 47,99$ dans un contexte de hausse des marchésNovember 13, 2024 | fr.investing.comBuy this Stock before Trump Takes Office!We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. And it's not just because it hit a critical "buy now" price.January 6, 2025 | Behind the Markets (Ad)Promising Potential and Strong Safety Profile Drive Buy Rating for Tectonic TherapeuticNovember 13, 2024 | markets.businessinsider.comTectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comL'action TECX atteint un plus haut de 52 semaines à 38,14$ dans un contexte d'optimisme du marchéOctober 25, 2024 | fr.investing.comLe titre TECX atteint un plus haut de 52 semaines à 34,54$ dans un contexte de rallye boursierOctober 15, 2024 | fr.investing.comTD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)September 24, 2024 | markets.businessinsider.comSee More Headlines AVRO Stock Analysis - Frequently Asked Questions How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) released its earnings results on Thursday, November, 4th. The company reported ($9.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($9.00). When did AVROBIO's stock split? AVROBIO's stock reverse split on the morning of Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did AVROBIO IPO? AVROBIO (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE). Company Calendar Last Earnings11/04/2021Today1/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.69 Trailing P/E Ratio2.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.52% Return on Assets-47.13% Debt Debt-to-Equity RatioN/A Current Ratio26.17 Quick Ratio26.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book0.66Miscellaneous Outstanding Shares44,890,000Free Float40,764,000Market Cap$62.85 million OptionableOptionable Beta1.23 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:AVRO) was last updated on 1/6/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVROBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.